6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Gastrointestinal B-OSE_Labeled_AE
Perforation I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Compromised B-OSE_Labeled_AE
Wound I-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Fistula B-OSE_Labeled_AE
Formation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Arterial B-OSE_Labeled_AE
Thromboembolic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Proteinuria B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Neutropenia B-OSE_Labeled_AE
and O
Neutropenic B-NonOSE_AE
Complications I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Diarrhea B-OSE_Labeled_AE
and O
Dehydration B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPLS I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
all O
grades O
, O
> O
=20 O
% O
incidence O
and O
at O
least O
2 O
% O
greater O
incidence O
for O
the O
ZALTRAP/FOLFIRI O
regimen O
) O
were O
leukopenia O
, O
diarrhea O
, O
neutropenia O
, O
proteinuria O
, O
AST O
increased O
, O
stomatitis O
, O
fatigue O
, O
thrombocytopenia O
, O
ALT O
increased O
, O
hypertension O
, O
weight O
decreased O
, O
decreased O
appetite O
, O
epistaxis O
, O
abdominal O
pain O
, O
dysphonia O
, O
serum O
creatinine O
increased O
, O
and O
headache O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
sanofi-aventis O
at O
1-800-633-1610 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
varying O
designs O
and O
in O
different O
patient O
populations O
, O
the O
adverse O
reaction O
rates O
reported O
in O
one O
clinical O
trial O
may O
not O
be O
easily O
compared O
to O
those O
rates O
reported O
in O
another O
clinical O
trial O
, O
and O
may O
not O
reflect O
the O
rates O
actually O
observed O
in O
clinical O
practice O
. O

The O
safety O
of O
ZALTRAP O
in O
combination O
with O
FOLFIRI O
was O
evaluated O
in O
1216 O
previously O
treated O
patients O
with O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
Study O
1 O
) O
who O
were O
treated O
with O
ZALTRAP O
4 O
mg O
per O
kg O
intravenous O
( O
N=611 O
) O
or O
placebo O
( O
N=605 O
) O
every O
two O
weeks O
( O
one O
cycle O
) O
in O
a O
randomized O
( O
1:1 O
) O
, O
double-blind O
, O
placebo-controlled O
Phase O
3 O
study O
. O

Patients O
received O
a O
median O
of O
9 O
cycles O
of O
ZALTRAP/FOLFIRI O
or O
8 O
cycles O
of O
placebo/FOLFIRI O
. O

The O
most O
common O
adverse O
reactions O
( O
all O
grades O
, O
> O
=20 O
% O
incidence O
) O
reported O
at O
a O
higher O
incidence O
( O
2 O
% O
or O
greater O
between-arm O
difference O
) O
in O
the O
ZALTRAP/FOLFIRI O
arm O
, O
in O
order O
of O
decreasing O
frequency O
, O
were O
leukopenia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
fatigue O
, O
thrombocytopenia B-OSE_Labeled_AE
, O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dysphonia B-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
( O
see O
Table O
1 O
) O
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
> O
=5 O
% O
) O
reported O
at O
a O
higher O
incidence O
( O
2 O
% O
or O
greater O
between-arm O
difference O
) O
in O
the O
ZALTRAP/FOLFIRI O
arm O
, O
in O
order O
of O
decreasing O
frequency O
, O
were O
neutropenia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
( O
see O
Table O
1 O
) O
. O

The O
most O
frequent O
adverse O
reactions O
leading O
to O
permanent O
discontinuation O
in O
> O
=1 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
regimen O
were O
asthenia B-OSE_Labeled_AE
/ O
fatigue B-OSE_Labeled_AE
, O
infections B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
proteinuria B-OSE_Labeled_AE
. O

The O
ZALTRAP O
dose O
was O
reduced O
and/or O
omitted O
in O
17 O
% O
of O
patients O
compared O
to O
placebo-dose O
modification O
in O
5 O
% O
of O
patients O
. O

Cycle O
delays O
> O
7 O
days O
occurred O
in O
60 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
with O
43 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

The O
most O
common O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
during O
study O
treatment O
in O
Study O
1 O
where O
the O
incidence O
was O
> O
=5 O
% O
( O
all O
grades O
) O
in O
patients O
receiving O
ZALTRAP O
in O
combination O
with O
FOLFIRI O
and O
which O
occurred O
at O
> O
=2 O
% O
higher O
frequency O
in O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
placebo/FOLFIRI O
are O
shown O
in O
Table O
1 O
. O

Table O
1 O
- O
Selected O
Adverse O
Reactions O
and O
Laboratory O
Findings O
in O
Study O
1 O
: O
Primary O
System O
Organ O
Class O
Preferred O
Term O
( O
% O
) O
Placebo/FOLFIRI O
( O
N=605 O
) O
ZALTRAP/FOLFIRI O
( O
N=611 O
) O
All O
grades O
Grades O
3-4 O
All O
grades O
Grades O
3-4 O
Note O
: O
Adverse O
Reactions O
are O
reported O
using O
MedDRA O
version O
MEDDRA13.1 O
and O
graded O
using O
NCI O
CTC O
version O
3.0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
6 O
% O
0.8 O
% O
9 O
% O
0.8 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
72 O
% O
12 O
% O
78 O
% O
16 O
% O
Neutropenia B-OSE_Labeled_AE
57 O
% O
30 O
% O
67 O
% O
37 O
% O
Thrombocytopenia B-OSE_Labeled_AE
35 O
% O
2 O
% O
48 O
% O
3 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
24 O
% O
2 O
% O
32 O
% O
3 O
% O
Dehydration B-OSE_Labeled_AE
3 O
% O
1 O
% O
9 O
% O
4 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
9 O
% O
0.3 O
% O
22 O
% O
2 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
11 O
% O
1.5 O
% O
41 O
% O
19 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
7 O
% O
0 O
28 O
% O
0.2 O
% O
Dysphonia B-OSE_Labeled_AE
3 O
% O
0 O
25 O
% O
0.5 O
% O
Dyspnea B-OSE_Labeled_AE
9 O
% O
0.8 O
% O
12 O
% O
0.8 O
% O
Oropharyngeal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
% O
0 O
8 O
% O
0.2 O
% O
Rhinorrhea B-OSE_Labeled_AE
2 O
% O
0 O
6 O
% O
0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
57 O
% O
8 O
% O
69 O
% O
19 O
% O
Stomatitis B-OSE_Labeled_AE
33 O
% O
5 O
% O
50 O
% O
13 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
24 O
% O
2 O
% O
27 O
% O
4 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Upper I-OSE_Labeled_AE
8 O
% O
1 O
% O
11 O
% O
1 O
% O
Hemorrhoids B-OSE_Labeled_AE
2 O
% O
0 O
6 O
% O
0 O
Rectal B-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
2 O
% O
0.5 O
% O
5 O
% O
0.7 O
% O
Proctalgia B-OSE_Labeled_AE
2 O
% O
0.3 O
% O
5 O
% O
0.3 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Plantar I-OSE_Labeled_AE
Erythrodysesthesia I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
4 O
% O
0.5 O
% O
11 O
% O
3 O
% O
Skin B-OSE_Labeled_AE
Hyperpigmentation I-OSE_Labeled_AE
3 O
% O
0 O
8 O
% O
0 O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
41 O
% O
1 O
% O
62 O
% O
8 O
% O
Serum B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
19 O
% O
0.5 O
% O
23 O
% O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
39 O
% O
8 O
% O
48 O
% O
13 O
% O
Asthenia B-OSE_Labeled_AE
13 O
% O
3 O
% O
18 O
% O
5 O
% O
Investigations B-NonOSE_AE
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
54 O
% O
2 O
% O
62 O
% O
3 O
% O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
39 O
% O
2 O
% O
50 O
% O
3 O
% O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
14 O
% O
0.8 O
% O
32 O
% O
3 O
% O
Infections B-OSE_Labeled_AE
occurred O
at O
a O
higher O
frequency O
in O
patients O
receiving O
ZALTRAP/FOLFIRI O
( O
46 O
% O
, O
all O
grades O
; O
12 O
% O
, O
Grade O
3-4 O
) O
than O
in O
patients O
receiving O
placebo/FOLFIRI O
( O
33 O
% O
, O
all O
grades O
; O
7 O
% O
, O
Grade O
3-4 O
) O
, O
including O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
catheter B-OSE_Labeled_AE
site I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
tooth B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
severe O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
with O
ZALTRAP/FOLFIRI O
( O
0.3 O
% O
) O
and O
placebo/FOLFIRI O
( O
0.5 O
% O
) O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
VTE I-OSE_Labeled_AE
) O
, O
consisting O
primarily O
of O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
occurred O
in O
9 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
7 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
VTE B-OSE_Labeled_AE
occurred O
in O
8 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
in O
6 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
occurred O
in O
5 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
3.4 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
a O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

In O
patients O
with O
various O
cancers B-Not_AE_Candidate
across O
15 O
studies O
, O
1.4 O
% O
( O
41/2862 O
) O
of O
patients O
tested O
positive B-NonOSE_AE
for I-NonOSE_AE
anti I-NonOSE_AE
- I-NonOSE_AE
product I-NonOSE_AE
antibody I-NonOSE_AE
( I-NonOSE_AE
APA I-NonOSE_AE
) O
at O
baseline O
. O

The O
incidence O
of O
APA B-OSE_Labeled_AE
development I-OSE_Labeled_AE
was O
3.1 O
% O
( O
53/1687 O
) O
in O
patients O
receiving O
intravenous O
ziv-aflibercept O
and O
1.7 O
% O
( O
19/1134 O
) O
in O
patients O
receiving O
placebo O
. O

Among O
patients O
who O
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
APA I-OSE_Labeled_AE
and O
had O
sufficient O
samples O
for O
further O
testing O
, O
neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were I-OSE_Labeled_AE
detected I-OSE_Labeled_AE
in O
17 O
of O
48 O
ziv-aflibercept-treated O
patients O
and O
in O
2 O
of O
40 O
patients O
receiving O
placebo O
. O

The O
mean O
free O
ziv-aflibercept O
trough O
concentrations O
were O
lower O
in O
patients O
with O
positive B-NonOSE_AE
neutralizing I-NonOSE_AE
antibodies I-NonOSE_AE
than O
in O
the O
overall O
population O
. O

The O
impact O
of O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
on O
efficacy O
and O
safety O
could O
not O
be O
assessed O
based O
on O
limited O
available O
data O
. O

Immunogenicity B-NonOSE_AE
data O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
, O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
ZALTRAP I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to O
other O
products O
may O
be O
misleading O
. O

